mcleanap

About mcleanap

This author has not yet filled in any details.
So far mcleanap has created 28 blog entries.
August 17, 2022

Advanced Proteome Therapeutics Manuscript Published in Bioconjugate Chemistry

2022-10-28T18:00:42-04:00

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), reports that its US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), is dedicating additional resources to its SARS-CoV-2 protease inhibitor program.

Advanced Proteome Therapeutics Manuscript Published in Bioconjugate Chemistry2022-10-28T18:00:42-04:00
August 3, 2022

Advanced Proteome Therapeutics Receives Issued Patent

2022-10-28T18:01:35-04:00

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), reports that its US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), is dedicating additional resources to its SARS-CoV-2 protease inhibitor program.

Advanced Proteome Therapeutics Receives Issued Patent2022-10-28T18:01:35-04:00
April 13, 2022

Advanced Proteome Therapeutics Receives Notice of Allowance for Patent Claims

2022-10-28T18:07:44-04:00

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), reports that its US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), is dedicating additional resources to its SARS-CoV-2 protease inhibitor program.

Advanced Proteome Therapeutics Receives Notice of Allowance for Patent Claims2022-10-28T18:07:44-04:00
March 18, 2022

Advanced Proteome Therapeutics Announces Warrant Extension

2022-10-28T18:04:11-04:00

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), reports that its US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), is dedicating additional resources to its SARS-CoV-2 protease inhibitor program.

Advanced Proteome Therapeutics Announces Warrant Extension2022-10-28T18:04:11-04:00
February 3, 2022

Advanced Proteome Therapeutics Update on Plans for 2022

2022-10-28T18:05:26-04:00

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), reports that its US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), is dedicating additional resources to its SARS-CoV-2 protease inhibitor program.

Advanced Proteome Therapeutics Update on Plans for 20222022-10-28T18:05:26-04:00
November 23, 2021

Advanced Proteome Therapeutics Expands Operations

2022-10-28T18:07:06-04:00

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), reports that its US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), is dedicating additional resources to its SARS-CoV-2 protease inhibitor program.

Advanced Proteome Therapeutics Expands Operations2022-10-28T18:07:06-04:00
August 24, 2021

Advanced Proteome Therapeutics Provides Update on Covid Program

2021-09-09T12:50:12-04:00

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), reports that its US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), is dedicating additional resources to its SARS-CoV-2 protease inhibitor program.

Advanced Proteome Therapeutics Provides Update on Covid Program2021-09-09T12:50:12-04:00
July 21, 2021

Advanced Proteome Therapeutics Announces Appointment of Dr. Benjamin Krantz to Ceo

2021-09-09T12:51:12-04:00

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce that as previously planned, Dr. Benjamin Krantz has taken over the role of CEO at its US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”).

Advanced Proteome Therapeutics Announces Appointment of Dr. Benjamin Krantz to Ceo2021-09-09T12:51:12-04:00
June 9, 2021

Advanced Proteome Therapeutics Announces Renowned Scientist to Join Scientific Advisory Board and New Chemistry Hire

2021-09-09T12:51:45-04:00

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), reports that its US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), has a appointed a new Scientific Advisory Board Member and hired a new lead chemist.

Advanced Proteome Therapeutics Announces Renowned Scientist to Join Scientific Advisory Board and New Chemistry Hire2021-09-09T12:51:45-04:00
April 13, 2021

Advanced Proteome Therapeutics Announces Closing Final Tranche of Non-brokered Private Placement

2021-09-09T12:52:14-04:00

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) is pleased to announce that, further to its news release of March 11, 2021 and subject to the approval of the TSX Venture Exchange, it has closed the final tranche of its non-brokered private placement (the “Private Placement”) raising gross proceeds of $524,610 by the issuance of 2,559,073 units at a price of $0.205 per unit.

Advanced Proteome Therapeutics Announces Closing Final Tranche of Non-brokered Private Placement2021-09-09T12:52:14-04:00
Go to Top